alexa
Reach Us +44-1647-403003
Borderline Ovarian Tumors (BOTs) | 43924
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Borderline ovarian tumors (BOTs)

Experts Meeting on Gynecologic Oncology

Ines Vasconcelos

Charite Medical University of Berlin, Germany

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.C1.063

Abstract
Borderline ovarian tumors (BOTs) were first described by Taylor in 1929 and have been a challenge for both pathologists and oncologists. BOT is a disease of younger, fertile women, generally with a benign course; however, a minority of patients progress and eventually succumb to the disease. Although the corrected survival for patients with disease confined to the ovary is 100% at 15 years, 30% of patients with serous BOT with invasive implants will develop persistent or recurrent tumor, most commonly low-grade ovarian serous carcinoma. For the group of patients with invasive implants, there is no consensus regarding standard therapy. At present, chemotherapy is offered mostly to patients with invasive implants, regardless of histological subtype. However, response to these agents remains suboptimal with recurrence estimates for patients for patients with BOT with invasive implants undergoing adjuvant treatment remaining high at 44.0%. In this presentation we will discuss the current evidence, or lack of thereof, to support the use of adjuvant treatment in patients with invasive implants in the primary treatment setting.
Biography

Ines Vasconcelos has completed her medical degree with honors at the University of Coimbra in Portugal and her Doctoral studies with Magna Cum Laude at the Charité Medical University in Germany. She has published in several international peer-reviewed high-impact journals and serves as an Editorial Board Member of the journal Advances in Modern Oncology Research (AMOR). She is currently working at the Berlin Oncological Center Kurfürstendamm.

Email: [email protected]

Relevant Topics
Top